Hematological Malignancies Drugs Market Size, Share & Trends Analysis Report By Drugs (Monoclonal Antibodies, CAR-T Cell Therapy), By Pipeline Products, By Indication (Leukemia, Lymphoma), By Region, And Segment Forecasts, 2024-2031

Report Id: 1211 Pages: 180 Last Updated: 20 August 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

The Hematological Malignancies Drugs Market Size is estimated to grow at a CAGR of 14.2% during the forecast period for 2024-2031. 

hematological malignancies

Hematologic malignancies are cancers that most often start in the bone marrow or the immune system cells. Lymphom, leukemia, and multiple myeloma are the three most common blood malignancies. The development of innovative agents has contributed to improved outcomes for cancer patients in recent years, resulting in significant advancement in the field of cancer therapy. The COVID19 pandemic, on the other hand, has hampered current cancer patient treatments. Because of their immunosuppression, patients with haematological malignancies appear to be extremely prone to Covid-19 infection.

The multiple factors driving the growth of the Hematological Malignancies Drugs Market  include the rising hematological malignancy cases, technological advances in therapy techniques, favourable regulatory environment, growing government funding for the R&D of innovative cancer therapies, spreading public awareness regarding the benefits of advanced blood cancer therapeutics, and the high demand for cost-efficient malignancy treatments. The increasing incidences of leukemia, lymphoma, and multiple myeloma cases led to the emergence of advanced therapeutics. For instance, in October 2021, Novartis acquired the US FDA approval for Scemblix (asciminib) to treat chronic myeloid leukemia (CML). Also, Bristol Myers Squibb (US) received U.S. FDA approval for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. Thus, R&D activities are expected to offer new growth opportunities for the Hematological Malignancies Drugs Market  in the forthcoming years. 

However, the high cost of therapies, complex manufacturing methods, and the side effects of emerging therapies may inhibit market augmentation over the forecast years.

Market Segmentation

The Hematological Malignancies Drugs Market  is classified based on drugs, pipeline products, indications, and region. By drugs, the market is segmented into monoclonal antibodies (Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab Vedotin), Arzerra (Ofatumumab)) and CAR-T cell therapy (Tecartus (Brexucabtagene Autoleucel), Kymriah (Tisagenlecleucel), Yescarta (Axicabtagene Ciloleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel)). By pipeline products, the market is grouped into monoclonal antibodies (Teclistamab, Iomab-B, Ublituximab, CS1001) and CAR-T cell therapy (Ciltacabtagene Autoleucel (JNJ-68284528)). The indications segment comprises leukemia (acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myeloid leukemia), lymphoma (Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma), and multiple myeloma. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

North America dominated the Hematological Malignancies Drugs Market  in 2023 and is expected to continue its trend over the forecast period (2024-2031) due to the surging R&D funding for malignancy therapeutics and the growing incidences of leukemia and lymphoma in this region.

Competitive Landscape

Some Of The Key Players In The Hematological Malignancies Drugs Market:

  • AbbVie Inc.,
  • Amgen Inc.,
  • Bristol-Myers Squibb Company,
  • Hoffmann-La Roche Ltd.,
  • Gilead Sciences, Inc.,
  • GlaxoSmithKline plc,
  • Immune-Onc Therapeutics, Inc.,
  • Johnson & Johnson Services, Inc.,
  • Merck & Co., Inc.,
  • Novartis International AG,
  • Pfizer Inc.,
  • Sanofi S.A.,
  • Takeda Pharmaceutical Company Limited,

The Hematological Malignancies Drugs Market Report Scope

Report Attribute Specifications
Market Size Value In 2023 USD XX Billion
Revenue Forecast In 2031 USD XX Billion
Growth Rate CAGR CAGR of 14.20% from 2024 to 2031
Quantitative Units Representation of revenue in US$ Billion and CAGR from 2024 to 2031
Historic Year 2019 to 2023
Forecast Year 2024-2031
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Drugs, By Pipeline Products, By Indication
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia
Competitive Landscape AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and others.
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing And Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation Of Hematological Malignancies Drugs Market

Global Hematological Malignancies Drugs Market , by Drugs

  • Monoclonal Antibodies
    • Blincyto (Blinatumomab)
    • Besponsa (Inotuzumab Ozogamicin)
    • Lumoxiti (Moxetumomab Pasudotox)
    • Mylotarg (Gemtuzumab Ozogamicin)
    • Opdivo (Nivolumab)
    • AiRuiKa (Camrelizumab)
    • Tyvyt (Sintilimab)
    • Tislelizumab
    • Gazyva (Obinutuzumab)
    • Zynlonta (Loncastuximab Tesirine-lpyl)
    • Darzalex (Daratumumab)
    • Blenrep (Belantamab Mafodotin-blmf)
    • Keytruda (Pembrolizumab)
    • Adcetris (Brentuximab Vedotin)
    • Arzerra (Ofatumumab
  • CAR-T Cell Therapy 
    • Tecartus (Brexucabtagene Autoleucel)
    • Kymriah (Tisagenlecleucel)
    • Yescarta (Axicabtagene Ciloleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel) 

hematological malignancies

Global Hematological Malignancies Drugs Market , by Pipeline Products

  • Monoclonal Antibodies
  • Teclistamab
  • Iomab-B
  • Ublituximab
  • CS1001
  • CAR-T Cell Therapy
  • Ciltacabtagene Autoleucel (JNJ-68284528)

Global Hematological Malignancies Drugs Market , by Indications

  • Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Lymphoma
  • Hodgkin’s Lymphoma
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma

Global Hematological Malignancies Drugs Market , by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North AmericaHematological Malignancies Drugs Market , by Country

  • U.S.
  • Canada

Europe Hematological Malignancies Drugs Market , by Country

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia PacificHematological Malignancies Drugs Market , by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Hematological Malignancies Drugs Market , by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Hematological Malignancies Drugs Market , by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immune-Onc Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Other Prominent Players

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
7347
Security Code field cannot be blank!

Frequently Asked Questions

Few key players operating in theHematological Malignancies Drugs Market are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Roche

The Hematological Malignancies Drugs Market Size is valued at XX Billion in 2023 and is predicted to reach XX Billion by the year 2031.

The Hematological Malignancies Drugs Market is expected to grow at a 14.20% CAGR during the forecast period for 2024-2031.
Get Sample Report Enquiry Before Buying